Abstract:
BACKGROUND:CD73 induces the dephosphorylation of adenosine monophosphate converting it to adenosine, enabling malignancies to escape from immune surveillance. Although CD73 overexpression has been reported to be a poor prognostic factor in several malignancies including non-small cell lung cancer (NSCLC), its predictive relevance in NSCLC patients receiving immune checkpoint inhibitors is unknown. The present research was conducted to investigate the prognostic significance of CD73 expression in NSCLC patients receiving immune checkpoint inhibitors (ICIs). METHODS:We screened 91 patients with advanced or recurrent NSCLC who received immune checkpoint inhibitors. CD73 expression was evaluated immunohistochemically using tissue specimens obtained just before treatment with ICIs. RESULTS:Analysis of progression-free survival (PFS) and overall survival (OS) in relation to several levels of CD73 expression (1%, 10%, 30%, and 50%) showed that both tended to be more favorable as expression of CD73 increased. PFS and OS were longer for patients in whom at least 50% of the tumor cells expressed CD73 than for those in whom <50% of the tumor cells did so. In patients who were positive for EGFR mutation, immune checkpoint inhibitors were significantly more effective in those with high CD73 expression, whereas CD73 expression did not significantly affect the efficacy in patients with EGFR mutation-negative NSCLC. Furthermore, CD73 expression was predictive factor for the PFS independent of PD-L1 expression in patients with EGFR mutation. CONCLUSIONS:High CD73 expression may predict a favorable response to ICIs in NSCLC patients, especially those harboring EGFR mutations. KEY POINTS:Significant findings of the study: In patients who were positive for EGFR mutation, immune checkpoint inhibitors (ICIs) were significantly more effective in those with high CD73 expression, whereas CD73 expression did not significantly affect the efficacy in patients with EGFR mutation-negative NSCLC. WHAT THIS STUDY ADDS:High CD73 expression may predict a favorable response to immune checkpoint inhibitors in NSCLC patients, especially those harboring EGFR mutations.
journal_name
Thorac Cancerjournal_title
Thoracic cancerauthors
Ishii H,Azuma K,Kawahara A,Kinoshita T,Matsuo N,Naito Y,Tokito T,Yamada K,Akiba J,Hoshino Tdoi
10.1111/1759-7714.13346subject
Has Abstractpub_date
2020-04-01 00:00:00pages
950-955issue
4eissn
1759-7706issn
1759-7714journal_volume
11pub_type
杂志文章相关文献
Thoracic Cancer文献大全abstract::Immune checkpoint inhibitors that block the programmed death 1/programmed death ligand 1 pathways are widely used to treat advanced lung cancers. There are seldom cases of histologic transformation reported after treatment with immunotherapy. Here, we report the case of a 69-year-old man with stage IV lung squamous ce...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13312
更新日期:2020-03-01 00:00:00
abstract:BACKGROUND:Previous studies have reported that soluble fms-like tyrosine kinase-1 (sFlt-1) possesses anti-tumor effects by inhibiting angiogenesis in many cancers. Exosomes can be engineered as delivery vehicles for transferring functional biomolecules, such as proteins, lipids, and nucleic acids (DNA, mRNA, and miRNA)...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13175
更新日期:2019-10-01 00:00:00
abstract:BACKGROUND:Surgery is the standard of care for early stage non-small cell lung cancer (NSCLC). Stereotactic body radiotherapy (SBRT) is another definitive treatment option for those patients who have not been treated surgically. Comparison of approaches is being explored in NSCLC, but has yet to be compared exclusively...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13260
更新日期:2020-02-01 00:00:00
abstract::Carcinosarcoma of the esophagus is a rare malignant neoplasm with both epithelial and mesenchymal (sarcomatous) components. We describe a case of a 72-year-old man with a huge esophageal tumor which could often have been considered inoperable. However, the patient underwent a curative resection and had a good prognosi...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/j.1759-7714.2011.00069.x
更新日期:2011-11-01 00:00:00
abstract:BACKGROUND:This study investigated the risk factors for severe weight loss (SWL) within one year after minimally invasive McKeown esophagectomy. METHODS:Esophageal cancer patients who underwent McKeown esophagectomy between January and July 2017 were prospectively enrolled. Preoperative body weight (PBW) was chosen as...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12934
更新日期:2019-02-01 00:00:00
abstract:BACKGROUND:Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) may be necessary for patients with incidental lung cancer during or after coronary intervention. Although EBUS-TBNA is quite safe, the safety in patients who recently received percutaneous coronary intervention (PCI) has not been de...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12846
更新日期:2018-11-01 00:00:00
abstract:BACKGROUND:Lung cancer is the leading cause of cancer-related deaths. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective for advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations, some patients experience little or no response. The Glasgow prognostic score (GPS...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13526
更新日期:2020-08-01 00:00:00
abstract:BACKGROUND:Many randomized clinical trials have demonstrated that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are advantageous over standard chemotherapy, either as front-line treatment or as further management of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). Howev...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12275
更新日期:2016-01-01 00:00:00
abstract:BACKGROUND:A single institution retrospective analysis of 124 non-small cell lung carcinoma (NSCLC) patients was performed to identify whether disease-free survival (DFS) achieves incremental values when radiomic and genomic data are combined with clinical information. METHODS:Using the least absolute shrinkage and se...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13568
更新日期:2020-09-01 00:00:00
abstract:BACKGROUND: The 12th National Lung Cancer Academic Conference was held in Wu Han, China in 2011. METHODS: The content of the conference involved recent research achievements and progress in the field of lung cancer, including the epidemiology of lung cancer and molecules, new methods and technology for early-screeni...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/j.1759-7714.2012.00125.x
更新日期:2012-08-01 00:00:00
abstract:BACKGROUND:We performed a retrospective analysis to compare the efficacy of whole brain radiotherapy (WBRT) combined with temozolomide (TMZ) versus WBRT alone as first-line treatment for brain metastases (BM). METHODS:Seventy-eight non-small cell lung cancer patients with BM were observed, including 45 patients who re...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12795
更新日期:2018-09-01 00:00:00
abstract:BACKGROUND:Our recent studies have indicated that miR-153-3p is downregulated in the esophageal squamous cell carcinoma (ESCC) cell lines and tissues. Upregulation of miR-153-3p was found to inhibit migration and invasion of ESCC cells. However, whether miR-153-3p regulates the cisplatin sensitivity in ESCC cells remai...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13326
更新日期:2020-03-01 00:00:00
abstract::Pulmonary pleomorphic carcinoma has been shown to respond remarkably to PD-1 inhibitors; however, the biomarkers for this therapy have not been fully proven. We report a case of pulmonary pleomorphic carcinoma with overexpressed PD-L1, in which a complete response to nivolumab was sustained for >14 months. Immunohisto...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12557
更新日期:2018-01-01 00:00:00
abstract::Enhanced recovery after surgery (ERAS) is a multiprofessional, multidisciplinary and evidence-based program that aims to reduce complications, improve overall prognosis, shorten hospital stays, and promote fast recovery following major surgery. Nurses play a crucial role in the successful implementation of the ERAS pr...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13372
更新日期:2020-04-01 00:00:00
abstract:BACKGROUND:MicroRNA-128 (miR-128) serves as a regulator by inducing cancer cell apoptosis, differentiation, the epithelial-to-mesenchymal transition process, and tumor growth by mediating different targets. NIMA-related kinase 2 (NEK2) is aberrantly expressed in lung cancer. The miR-128/NEK2 pathway has been reported t...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12442
更新日期:2017-07-01 00:00:00
abstract:BACKGROUND:S-1 monotherapy is effective and feasible for previously treated patients with advanced non-small cell lung cancer (NSCLC). However, it is not clear whether its effectiveness and tolerability in elderly patients are equivalent to those in younger patients. Hence, this study aimed to evaluate the efficacy and...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13622
更新日期:2020-10-01 00:00:00
abstract::Acquired respiratory-digestive tract fistulas occur with abnormal communication between the airways and digestive tract, causing the interflow of gas and liquid. Despite advances in surgical methods and the development of multimodal therapy in recent years, patients with acquired respiratory-digestive tract fistulas c...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12856
更新日期:2018-11-01 00:00:00
abstract::For refractory or resistant small cell lung cancer (SCLC), there is no standard treatment. We report a case of refractory SCLC achieving complete remission and then developing fatal interstitial pneumonitis after treatment with single-agent nab-paclitaxel. The relevant literature has also been reviewed. In terms of ef...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/j.1759-7714.2011.00086.x
更新日期:2012-02-01 00:00:00
abstract:BACKGROUND:Several studies have previously demonstrated the survival benefit of both EGFR-TKI treatment and chemotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. The aim of the present study was to clarify the factors influencing the treatment sequence after failure of EGFR-TKI ther...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13360
更新日期:2020-04-01 00:00:00
abstract:BACKGROUND:Although FGF19 gene aberrations are associated with carcinogenesis and progression in human cancers, the roles of FGF19 genetic amplification and expression in Chinese patients with lung squamous cell carcinoma (LSCC) and FGF19 amplification as a potential therapeutic target for LSCC are not well understood....
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12504
更新日期:2017-11-01 00:00:00
abstract:BACKGROUND:Breast cancer is the most common cancer among women. Population-based cancer registration data from the National Central Cancer Registry were used to analyze and evaluate the incidence and mortality rates in China in 2013, providing scientific information for cancer prevention and control. METHODS:Pooled da...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12426
更新日期:2017-05-01 00:00:00
abstract:BACKGROUND:Capn4 and ZEB1 play important roles in the metastasis of several types of cancer. However, the roles and relationship of Capn4 and ZEB1 in esophageal squamous cell carcinoma (ESCC) remain unclear. METHODS:ESCC tumor tissues and corresponding normal esophageal epithelial tissues were obtained from 86 patient...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12893
更新日期:2019-01-01 00:00:00
abstract::Almost all epidermal growth factor receptor (EGFR)-mutant lung cancers develop resistance to EGFR-tyrosine kinase inhibitors. Several mechanisms for this acquired resistance have been identified, including development of an EGFR T790M mutation, MET amplification, hepatocyte growth factor overexpression, loss of phosph...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.12484
更新日期:2017-11-01 00:00:00
abstract:BACKGROUND:Nm23-H1 gene has been found to be an inhibitor of tumor metastasis in lung cancer. MicroRNAs (miRNAs) play key roles in tumor metastasis through multiple signaling pathways. This study explored whether the nm23-H1 gene could inhibit invasion and metastasis of lung cancer cells by regulating miRNA-660-5p targ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13308
更新日期:2020-03-01 00:00:00
abstract:BACKGROUND:Lung cancer is a disease with a poor prognosis and psychological impact. Lung cancer causes both physical and psychological burdens on patients, and financial burdens on families and society. The aim of this study was to examine the relationship between depression and influencing factors in non-small-cell lu...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12179
更新日期:2015-05-01 00:00:00
abstract::After sternal tumor resection, reconstruction of chest wall defects is still a challenging part of thoracic surgery. Three-dimensional (3D)-printed titanium alloy prosthesis implants provide an effective solution. The bionic bone trabecular micropore structure, which is beneficial to the human body, increases stabilit...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13655
更新日期:2020-11-01 00:00:00
abstract::Pleomorphic adenoma is the most common type of salivary gland tumor. Although it rarely affects the trachea and bronchus, it usually grows in the airway and presents as an endobronchial mass. We recently experienced a case of pleomorphic adenoma originating in the bronchus and growing outward into the mediastinum. We ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12013
更新日期:2014-01-01 00:00:00
abstract::SMARCA4-deficient thoracic sarcoma (SMARCA4-DTS) is a new clinical entity characterized by SMARCA4 inactivation and has a dismal prognosis because of rapid growth. Effective treatments for SMARCA4-DTS have not yet been developed. Most recently, anti-programmed cell death 1 receptor (PD-1) blockade has been effective f...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13215
更新日期:2019-12-01 00:00:00
abstract:BACKGROUND:Non-small cell lung cancer (NSCLC) is a major type of lung cancer with high morbidity and high mortality. miR-874 has been determined to play a role in tumor suppression in several cancers. The purpose of our study was to detect the biological mechanisms of miR-874 and AQP3 in NSCLC. METHODS:CCK-8 and Trans...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13428
更新日期:2020-06-01 00:00:00
abstract:BACKGROUND:The combination of EGFR tyrosine kinase inhibitors (TKIs) and chemotherapy is thought to increase treatment efficacy in non-small-cell lung cancer (NSCLC). This study investigated the efficacy and potential mechanisms of different combined modes of icotinib plus pemetrexed in EGFR-mutant lung adenocarcinoma ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12818
更新日期:2018-09-01 00:00:00